Tempus AI offers a strong business model with AI-driven genomic data, resilient demand, and significant growth prospects.

Tempus AI's growth is fueled by data services and acquisitions, despite financial risks. Key Q2 results may shape its path to ...

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” second-quarter ...

TEM stock rallies 7.3% after the FDA clears its second cardiology AI tool, witnessing a 48% surge in just three months.

Tempus AI and NVIDIA are both actively working at the intersection of AI and healthcare. Tempus AI, while advancing precision ...

Tempus AI is a growth stock that is down 31% from all-time highs. Here's why TEM AI stock could be a part of your TFSA portfolio right now.

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

Former House Speaker Nancy Pelosi said back in 2022 the Senate would soon vote on a bill banning members of Congress from trading individual stocks. Roughly three years later, Pelosi is no ...

Tempus AI (NASDAQ:TEM) shares declined 2.6% after the precision medicine technology firm revealed plans for a $400 million offering of convertible senior notes due in 2030. The Chicago-based ...

Analysts have recently evaluated Tempus AI and provided 12-month price targets. The average target is $67.88, accompanied by a high estimate of $70.00 and a low estimate of $60.00. Observing a 7. ...

Recognizing that breast cancer guidelines, much like those for lung cancer, are constantly evolving, Tempus is working to ...

TEM Stock Outperforms Industry & Benchmark In the past year, Tempus AI shares have surged 58.6%, outperforming the industry’s 16.8% growth and the S&P 500 composite’s 11% improvement.